Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sri B. M. Patil Medical College, Bijapur, Karnataka, India | UNKNOWN |
| Jawaharlal Nehru Medical College | OTHER |
| University of Illinois at Chicago | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares two community-level strategies: selective administration of 800 mcg sublingual misoprostol to women at 350 mL blood loss for secondary prevention of postpartum hemorrhage (PPH) with universal use of 600 mcg oral misoprostol at the time of delivery for primary prevention of PPH. The study hypothesizes that at community-level births, secondary prevention for women is non-inferior (based on clinical parameters) to universal prophylaxis provided to women for primary prevention of PPH. This cluster-design non-inferiority trial has the potential to inform service delivery programs on clinical outcomes, program feasibility, cost and acceptability of two different community models of PPH care using misoprostol.
Rationale for Research: There is an absence of concrete data on the programmatic and cost-effectiveness of different service delivery models for prevention and treatment of postpartum hemorrhage with misoprostol, prompting a discussion of whether resources are best spent on misoprostol for primary prevention at lower levels (with treatment carried out at higher levels via referral) or whether immediate proactive treatment strategies should be considered. As the training and policy implications of universal prevention versus selective treatment approaches vary, simple and effective service delivery models are urgently needed to help governments and organizations decide how to best focus their limited resources. This study proposes to study the efficacy of a hybrid strategy (i.e., secondary prevention) that combines elements of prevention and treatment. Results of this study could provide a new model of care that will medicate fewer women, save costs and address the clinical conundrum of guessing at the safety of administering a prevention dose of misoprostol followed quickly by a larger treatment dose.
Study design: This randomized cluster trial will recruit women with deliveries attended by auxiliary nurse midwives (ANMs) that occur at homes or at health sub-centers. ANMs will be randomized to administer the intervention as described in the primary or secondary prevention arm.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary prevention | Other |
| |
| Secondary Prevention | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Misoprostol | Drug | Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of women with post-delivery hemoglobin ≤ 7.8 gm/dL | A 20% rate of post delivery Hb ≤7.8 gm/dL in the study arm with women receiving selective administration of 800 mcg sublingual misoprostol is non-inferior to a 13% rate of post delivery Hb ≤ 7.8 gm/dL in the study arm with women receiving universal 600 mcg oral misoprostol prophylaxis. | 72 hours (plus or minus 8 hours) after delivery |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of transfer to referral facilities for PPH | Proportion of women who are transferred from the location of delivery to higher level of care because the birth attendent diagnosed or suspected PPH. | within 72 hours (plus or minus 8 hours) after delivery |
| Rate of PPH |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. high-risk pregnancy
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Beverly Winikoff, MD, MPH | Gynuity Health Projects | Principal Investigator |
| Sheila Raghavan, MSc | Gynuity Health Projects | Principal Investigator |
| Stacie Gellar, PhD | University of Illinois at Chicago | Principal Investigator |
| Suellen Miller, PhD, CNM | University of California, San Francisco | Principal Investigator |
| Shivaprasad S Goudar, MD, MHPE | Jawaharlal Nehru Medical College | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Deliveries at health sub-centers and homes | Vijayapura | Karnataka | 586103 | India |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33232518 | Derived | Parry Smith WR, Papadopoulou A, Thomas E, Tobias A, Price MJ, Meher S, Alfirevic Z, Weeks AD, Hofmeyr GJ, Gulmezoglu AM, Widmer M, Oladapo OT, Vogel JP, Althabe F, Coomarasamy A, Gallos ID. Uterotonic agents for first-line treatment of postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2020 Nov 24;11(11):CD012754. doi: 10.1002/14651858.CD012754.pub2. |
| Label | URL |
|---|---|
| Gynuity Health Projects website | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D006473 | Postpartum Hemorrhage |
| ID | Term |
|---|---|
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D016595 | Misoprostol |
| ID | Term |
|---|---|
| D011459 | Prostaglandins E, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
Not provided
Not provided
| University of California, San Francisco |
| OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Misoprostol | Drug | Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby |
|
Proportion of women with 500 mL-999 mL blood loss following delivery, as measured by a calibrated blood collection drape. |
| within 1 hour after delivery |
| Rate of severe PPH | Proportion of women with > 1000 mL blood loss following delivery, as measured by a calibrated blood collection drape. | within 1 hour after delivery |
| Rate of adverse events | Adverse events include prolonged hospitalization, permanent or serious disability, additional threat to life, or death. | Within 72 hours (plus or minus 8 hours) after delivery |
| Mean blood loss | Blood loss will be measured using a blood collection drape, calibrated at 50 mL intervals. | 1 hour after delivery |
| Rate of additional interventions needed to control bleeding | Addtional interventions include administration of other uterotonics (e.g., oxytocin), IV fluids, comprehensive emergency obstetric care, blood transfusion and surgery | within 72 hours (plus or minus 8 hours) after delivery |
| Cost-effectiveness | The cost-effectiveness of the two interventions will be compared. The cost-effectiveness measure will utilize information collected on cost of the study drug, materials used to control bleeding, and the cost of transfer and subsequent care received by women who are in in need of higher level care. | 72 hours (plus or minus 8 hours) after delivery |
| Proportion of women reporting known side effects of misoprostol | Recognized side-effects of misoprostol include: Shivering, fever, headache, nausea, vomiting and diarrhea. Rare side effects include: abdominal pain from uterine cramping, seizures and palpitations (only with overdosing). All women in both study arms, including those in the secondary prevention arm who do not receive the study drug, will be asked if they experienced any of these symptoms. | 1 hour after delivery |
| Acceptability of intervention to women | A brief exit interview will be conducted with participants to assess their acceptability of the intervention, including tolerability of any side effects experienced. | 72 hours (plus or minus 8 hours) after delivery |
| D011644 | Puerperal Disorders |
| D014592 | Uterine Hemorrhage |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005231 |
| Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |